149 related articles for article (PubMed ID: 28296564)
1. AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells.
Webster PJ; Littlejohns AT; Gaunt HJ; Prasad KR; Beech DJ; Burke DA
Cell Cycle; 2017; 16(22):2176-2182. PubMed ID: 28296564
[TBL] [Abstract][Full Text] [Related]
2. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
3. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
4. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
[TBL] [Abstract][Full Text] [Related]
5. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
[TBL] [Abstract][Full Text] [Related]
6. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.
Ford JB; Baturin D; Burleson TM; Van Linden AA; Kim YM; Porter CC
Oncotarget; 2015 Sep; 6(29):28001-10. PubMed ID: 26334102
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
8. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
Hartman SJ; Bagby SM; Yacob BW; Simmons DM; MacBeth M; Lieu CH; Davis SL; Leal AD; Tentler JJ; Diamond JR; Eckhardt SG; Messersmith WA; Pitts TM
Front Oncol; 2021; 11():642328. PubMed ID: 33869031
[TBL] [Abstract][Full Text] [Related]
9. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
11. Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition.
Diab A; Kao M; Kehrli K; Kim HY; Sidorova J; Mendez E
Mol Cancer Res; 2019 May; 17(5):1115-1128. PubMed ID: 30679201
[TBL] [Abstract][Full Text] [Related]
12. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair.
Srinivas US; Dyczkowski J; Beißbarth T; Gaedcke J; Mansour WY; Borgmann K; Dobbelstein M
Oncotarget; 2015 May; 6(14):12574-86. PubMed ID: 25909291
[TBL] [Abstract][Full Text] [Related]
14. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
[TBL] [Abstract][Full Text] [Related]
15. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
16. AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.
Meng X; Bi J; Li Y; Yang S; Zhang Y; Li M; Liu H; Li Y; Mcdonald ME; Thiel KW; Wen KK; Wang X; Wu M; Leslie KK
Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29783721
[TBL] [Abstract][Full Text] [Related]
17. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
[TBL] [Abstract][Full Text] [Related]
18. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
19. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
[TBL] [Abstract][Full Text] [Related]
20. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
